Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 121 entries
Sorted by: Best Match Show Resources per page
Erratum to: Phase I and pharmacokinetic evaluation of the anti-telomerase agent KML-001 with cisplatin in advanced solid tumors.

Cancer chemotherapy and pharmacology

Edelman MJ, Lapidus R, Feliciano J, Styblo M, Beumer JH, Liu T, Gobburu J.
PMID: 27677624
Cancer Chemother Pharmacol. 2016 Nov;78(5):969. doi: 10.1007/s00280-016-3159-7.

No abstract available.

Cite
Edelman MJ, Lapidus R, Feliciano J, et al. Erratum to: Phase I and pharmacokinetic evaluation of the anti-telomerase agent KML-001 with cisplatin in advanced solid tumors. Cancer Chemother Pharmacol. 2016;78(5):969doi: 10.1007/s00280-016-3159-7.
Edelman, M. J., Lapidus, R., Feliciano, J., Styblo, M., Beumer, J. H., Liu, T., & Gobburu, J. (2016). Erratum to: Phase I and pharmacokinetic evaluation of the anti-telomerase agent KML-001 with cisplatin in advanced solid tumors. Cancer chemotherapy and pharmacology, 78(5), 969. https://doi.org/10.1007/s00280-016-3159-7
Edelman, Martin J, et al. "Erratum to: Phase I and pharmacokinetic evaluation of the anti-telomerase agent KML-001 with cisplatin in advanced solid tumors." Cancer chemotherapy and pharmacology vol. 78,5 (2016): 969. doi: https://doi.org/10.1007/s00280-016-3159-7
Edelman MJ, Lapidus R, Feliciano J, Styblo M, Beumer JH, Liu T, Gobburu J. Erratum to: Phase I and pharmacokinetic evaluation of the anti-telomerase agent KML-001 with cisplatin in advanced solid tumors. Cancer Chemother Pharmacol. 2016 Nov;78(5):969. doi: 10.1007/s00280-016-3159-7. PMID: 27677624.
Copy Download .nbib Format: NLM
Morphologic changes of Doxorubicin-sensitive and resistant lovo cells treated in-vitro by calcium channels blockers.

Oncology reports

Dancona S, Mazzo M.
PMID: 21597749
Oncol Rep. 1995 May;2(3):417-21. doi: 10.3892/or.2.3.417.

A morphological analysis by scanning electron microscopy (SEM) of the effect of two Ca++ channel blockers (verapamil and dilazep) on LoVo S (doxorubicin sensitive) and LoVo R (doxorubicin resistant) plated together with 3T3 in order to cause an experimental...

Cite
Dancona S, Mazzo M. Morphologic changes of Doxorubicin-sensitive and resistant lovo cells treated in-vitro by calcium channels blockers. Oncol Rep. 1995;2(3):417-21doi: 10.3892/or.2.3.417.
Dancona, S., & Mazzo, M. (1995). Morphologic changes of Doxorubicin-sensitive and resistant lovo cells treated in-vitro by calcium channels blockers. Oncology reports, 2(3), 417-21. https://doi.org/10.3892/or.2.3.417
Dancona, S, and Mazzo, M. "Morphologic changes of Doxorubicin-sensitive and resistant lovo cells treated in-vitro by calcium channels blockers." Oncology reports vol. 2,3 (1995): 417-21. doi: https://doi.org/10.3892/or.2.3.417
Dancona S, Mazzo M. Morphologic changes of Doxorubicin-sensitive and resistant lovo cells treated in-vitro by calcium channels blockers. Oncol Rep. 1995 May;2(3):417-21. doi: 10.3892/or.2.3.417. PMID: 21597749.
Copy Download .nbib Format: NLM
Correction to: Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma.

Cancer chemotherapy and pharmacology

Badruddoja MA, Pazzi M, Sanan A, Schroeder K, Kuzma K, Norton T, Scully T, Mahadevan D, Ahmadi MM.
PMID: 29034406
Cancer Chemother Pharmacol. 2018 Jan;81(1):223. doi: 10.1007/s00280-017-3448-9.

No abstract available.

Cite
Badruddoja MA, Pazzi M, Sanan A, et al. Correction to: Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma. Cancer Chemother Pharmacol. 2018;81(1):223doi: 10.1007/s00280-017-3448-9.
Badruddoja, M. A., Pazzi, M., Sanan, A., Schroeder, K., Kuzma, K., Norton, T., Scully, T., Mahadevan, D., & Ahmadi, M. M. (2018). Correction to: Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma. Cancer chemotherapy and pharmacology, 81(1), 223. https://doi.org/10.1007/s00280-017-3448-9
Badruddoja, Michael A, et al. "Correction to: Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma." Cancer chemotherapy and pharmacology vol. 81,1 (2018): 223. doi: https://doi.org/10.1007/s00280-017-3448-9
Badruddoja MA, Pazzi M, Sanan A, Schroeder K, Kuzma K, Norton T, Scully T, Mahadevan D, Ahmadi MM. Correction to: Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma. Cancer Chemother Pharmacol. 2018 Jan;81(1):223. doi: 10.1007/s00280-017-3448-9. PMID: 29034406.
Copy Download .nbib Format: NLM
Correction to: A phase I, randomized, single-dose study evaluating the pharmacokinetic equivalence of biosimilar ABP 215 and bevacizumab in healthy adult men.

Cancer chemotherapy and pharmacology

Markus R, Chow V, Pan Z, Hanes V.
PMID: 29159475
Cancer Chemother Pharmacol. 2018 Feb;81(2):419. doi: 10.1007/s00280-017-3457-8.

The article [A phase I, randomized, single-dose study evaluating the pharmacokinetic equivalence of biosimilar ABP 215 and bevacizumab in healthy adult men].

Cite
Markus R, Chow V, Pan Z, et al. Correction to: A phase I, randomized, single-dose study evaluating the pharmacokinetic equivalence of biosimilar ABP 215 and bevacizumab in healthy adult men. Cancer Chemother Pharmacol. 2018;81(2):419doi: 10.1007/s00280-017-3457-8.
Markus, R., Chow, V., Pan, Z., & Hanes, V. (2018). Correction to: A phase I, randomized, single-dose study evaluating the pharmacokinetic equivalence of biosimilar ABP 215 and bevacizumab in healthy adult men. Cancer chemotherapy and pharmacology, 81(2), 419. https://doi.org/10.1007/s00280-017-3457-8
Markus, Richard, et al. "Correction to: A phase I, randomized, single-dose study evaluating the pharmacokinetic equivalence of biosimilar ABP 215 and bevacizumab in healthy adult men." Cancer chemotherapy and pharmacology vol. 81,2 (2018): 419. doi: https://doi.org/10.1007/s00280-017-3457-8
Markus R, Chow V, Pan Z, Hanes V. Correction to: A phase I, randomized, single-dose study evaluating the pharmacokinetic equivalence of biosimilar ABP 215 and bevacizumab in healthy adult men. Cancer Chemother Pharmacol. 2018 Feb;81(2):419. doi: 10.1007/s00280-017-3457-8. PMID: 29159475; PMCID: PMC5778164.
Copy Download .nbib Format: NLM
Correction to: Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a .

Cancer chemotherapy and pharmacology

van Andel L, Rosing H, Zhang Z, Hughes L, Kansra V, Sanghvi M, Tibben MM, Gebretensae A, Schellens JHM, Beijnen JH.
PMID: 29181573
Cancer Chemother Pharmacol. 2018 Jan;81(1):47. doi: 10.1007/s00280-017-3474-7.

The article ''Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a

Cite
van Andel L, Rosing H, Zhang Z, et al. Correction to: Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a . Cancer Chemother Pharmacol. 2018;81(1):47doi: 10.1007/s00280-017-3474-7.
van Andel, L., Rosing, H., Zhang, Z., Hughes, L., Kansra, V., Sanghvi, M., Tibben, M. M., Gebretensae, A., Schellens, J. H. M., & Beijnen, J. H. (2018). Correction to: Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a . Cancer chemotherapy and pharmacology, 81(1), 47. https://doi.org/10.1007/s00280-017-3474-7
van Andel, L, et al. "Correction to: Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a ." Cancer chemotherapy and pharmacology vol. 81,1 (2018): 47. doi: https://doi.org/10.1007/s00280-017-3474-7
van Andel L, Rosing H, Zhang Z, Hughes L, Kansra V, Sanghvi M, Tibben MM, Gebretensae A, Schellens JHM, Beijnen JH. Correction to: Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a . Cancer Chemother Pharmacol. 2018 Jan;81(1):47. doi: 10.1007/s00280-017-3474-7. PMID: 29181573; PMCID: PMC5754421.
Copy Download .nbib Format: NLM
Correction to: Population pharmacokinetics of PF‑05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin.

Cancer chemotherapy and pharmacology

Chen X, Li C, Ewesuedo R, Yin D.
PMID: 31292683
Cancer Chemother Pharmacol. 2019 Sep;84(3):667. doi: 10.1007/s00280-019-03890-7.

The article "Population pharmacokinetics of PF-05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin

Cite
Chen X, Li C, Ewesuedo R, et al. Correction to: Population pharmacokinetics of PF‑05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin. Cancer Chemother Pharmacol. 2019;84(3):667doi: 10.1007/s00280-019-03890-7.
Chen, X., Li, C., Ewesuedo, R., & Yin, D. (2019). Correction to: Population pharmacokinetics of PF‑05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin. Cancer chemotherapy and pharmacology, 84(3), 667. https://doi.org/10.1007/s00280-019-03890-7
Chen, Xiaoying, et al. "Correction to: Population pharmacokinetics of PF‑05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin." Cancer chemotherapy and pharmacology vol. 84,3 (2019): 667. doi: https://doi.org/10.1007/s00280-019-03890-7
Chen X, Li C, Ewesuedo R, Yin D. Correction to: Population pharmacokinetics of PF‑05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin. Cancer Chemother Pharmacol. 2019 Sep;84(3):667. doi: 10.1007/s00280-019-03890-7. PMID: 31292683; PMCID: PMC6682847.
Copy Download .nbib Format: NLM
Evaluation of the bioequivalence and food effect on the bioavailability of CC-486 (oral azacitidine) tablets in adult patients with cancer.

Cancer chemotherapy and pharmacology

Babiker HM, Milhem M, Aisner J, Edenfield W, Shepard D, Savona M, Iyer S, Abdelrahim M, Beach CL, Skikne B, Laille E, Tsai KT, Ho T.
PMID: 32036412
Cancer Chemother Pharmacol. 2020 Mar;85(3):621-626. doi: 10.1007/s00280-020-04037-9. Epub 2020 Feb 08.

PURPOSE: CC-486 is an oral formulation of azacitidine that allows for extended dosing schedules to prolong azacitidine exposure to malignant cells and maximize clinical activity. CC-486 300 mg daily, administered for 14 or 21 days of 28-day treatment cycles,...

Cite
Babiker HM, Milhem M, Aisner J, et al. Evaluation of the bioequivalence and food effect on the bioavailability of CC-486 (oral azacitidine) tablets in adult patients with cancer. Cancer Chemother Pharmacol. 2020;85(3):621-626doi: 10.1007/s00280-020-04037-9.
Babiker, H. M., Milhem, M., Aisner, J., Edenfield, W., Shepard, D., Savona, M., Iyer, S., Abdelrahim, M., Beach, C. L., Skikne, B., Laille, E., Tsai, K. T., & Ho, T. (2020). Evaluation of the bioequivalence and food effect on the bioavailability of CC-486 (oral azacitidine) tablets in adult patients with cancer. Cancer chemotherapy and pharmacology, 85(3), 621-626. https://doi.org/10.1007/s00280-020-04037-9
Babiker, Hani M, et al. "Evaluation of the bioequivalence and food effect on the bioavailability of CC-486 (oral azacitidine) tablets in adult patients with cancer." Cancer chemotherapy and pharmacology vol. 85,3 (2020): 621-626. doi: https://doi.org/10.1007/s00280-020-04037-9
Babiker HM, Milhem M, Aisner J, Edenfield W, Shepard D, Savona M, Iyer S, Abdelrahim M, Beach CL, Skikne B, Laille E, Tsai KT, Ho T. Evaluation of the bioequivalence and food effect on the bioavailability of CC-486 (oral azacitidine) tablets in adult patients with cancer. Cancer Chemother Pharmacol. 2020 Mar;85(3):621-626. doi: 10.1007/s00280-020-04037-9. Epub 2020 Feb 08. PMID: 32036412; PMCID: PMC7036073.
Copy Download .nbib Format: NLM
Influence of FPGS, ABCC4, SLC29A1, and MTHFR genes on the pharmacogenomics of fluoropyrimidines in patients with gastrointestinal cancer from the Brazilian Amazon.

Cancer chemotherapy and pharmacology

Fernandes MR, Rodrigues JCG, Dobbin EAF, Pastana LF, da Costa DF, Barra WF, Modesto AAC, de Assumpção PB, da Costa Silva AL, Dos Santos SEB, Burbano RMR, de Assumpção PP, Dos Santos NPC.
PMID: 34331561
Cancer Chemother Pharmacol. 2021 Nov;88(5):837-844. doi: 10.1007/s00280-021-04327-w. Epub 2021 Jul 31.

PURPOSE: Fluoropyrimidines are one of the most used drug class to treat cancer patients, although they show high levels of associated toxicity. This study analyzed 33 polymorphisms in 17 pharmacogenes involved with the pharmacogenomics of fluoropyrimidines, in gastrointestinal cancer...

Cite
Fernandes MR, Rodrigues JCG, Dobbin EAF, et al. Influence of FPGS, ABCC4, SLC29A1, and MTHFR genes on the pharmacogenomics of fluoropyrimidines in patients with gastrointestinal cancer from the Brazilian Amazon. Cancer Chemother Pharmacol. 2021;88(5):837-844doi: 10.1007/s00280-021-04327-w.
Fernandes, M. R., Rodrigues, J. C. G., Dobbin, E. A. F., Pastana, L. F., da Costa, D. F., Barra, W. F., Modesto, A. A. C., de Assumpção, P. B., da Costa Silva, A. L., Dos Santos, S. E. B., Burbano, R. M. R., de Assumpção, P. P., & Dos Santos, N. P. C. (2021). Influence of FPGS, ABCC4, SLC29A1, and MTHFR genes on the pharmacogenomics of fluoropyrimidines in patients with gastrointestinal cancer from the Brazilian Amazon. Cancer chemotherapy and pharmacology, 88(5), 837-844. https://doi.org/10.1007/s00280-021-04327-w
Fernandes, Marianne Rodrigues, et al. "Influence of FPGS, ABCC4, SLC29A1, and MTHFR genes on the pharmacogenomics of fluoropyrimidines in patients with gastrointestinal cancer from the Brazilian Amazon." Cancer chemotherapy and pharmacology vol. 88,5 (2021): 837-844. doi: https://doi.org/10.1007/s00280-021-04327-w
Fernandes MR, Rodrigues JCG, Dobbin EAF, Pastana LF, da Costa DF, Barra WF, Modesto AAC, de Assumpção PB, da Costa Silva AL, Dos Santos SEB, Burbano RMR, de Assumpção PP, Dos Santos NPC. Influence of FPGS, ABCC4, SLC29A1, and MTHFR genes on the pharmacogenomics of fluoropyrimidines in patients with gastrointestinal cancer from the Brazilian Amazon. Cancer Chemother Pharmacol. 2021 Nov;88(5):837-844. doi: 10.1007/s00280-021-04327-w. Epub 2021 Jul 31. PMID: 34331561.
Copy Download .nbib Format: NLM
Antitumor efficacy of CHMFL-KIT-110 solid dispersion in mouse xenograft models of human gastrointestinal stromal tumors.

Cancer chemotherapy and pharmacology

Wang S, Wang C, Wang X, Wang X, Huang L, Kuai J, Wei W, Lu X, Yan S.
PMID: 34309733
Cancer Chemother Pharmacol. 2021 Nov;88(5):795-804. doi: 10.1007/s00280-021-04332-z. Epub 2021 Jul 26.

PURPOSE: CHMFL-KIT-110, a selective c-KIT kinase inhibitor for gastrointestinal stromal tumors (GISTs), possesses a poorly water-soluble, limiting the further development of the drug. This study was to investigate the antitumor efficacy of CHMFL-KIT-110 and CHMFL-KIT-110 solid dispersion (laboratory code:...

Cite
Wang S, Wang C, Wang X, et al. Antitumor efficacy of CHMFL-KIT-110 solid dispersion in mouse xenograft models of human gastrointestinal stromal tumors. Cancer Chemother Pharmacol. 2021;88(5):795-804doi: 10.1007/s00280-021-04332-z.
Wang, S., Wang, C., Wang, X., Wang, X., Huang, L., Kuai, J., Wei, W., Lu, X., & Yan, S. (2021). Antitumor efficacy of CHMFL-KIT-110 solid dispersion in mouse xenograft models of human gastrointestinal stromal tumors. Cancer chemotherapy and pharmacology, 88(5), 795-804. https://doi.org/10.1007/s00280-021-04332-z
Wang, Shengfu, et al. "Antitumor efficacy of CHMFL-KIT-110 solid dispersion in mouse xenograft models of human gastrointestinal stromal tumors." Cancer chemotherapy and pharmacology vol. 88,5 (2021): 795-804. doi: https://doi.org/10.1007/s00280-021-04332-z
Wang S, Wang C, Wang X, Wang X, Huang L, Kuai J, Wei W, Lu X, Yan S. Antitumor efficacy of CHMFL-KIT-110 solid dispersion in mouse xenograft models of human gastrointestinal stromal tumors. Cancer Chemother Pharmacol. 2021 Nov;88(5):795-804. doi: 10.1007/s00280-021-04332-z. Epub 2021 Jul 26. PMID: 34309733.
Copy Download .nbib Format: NLM
Covariate effects and population pharmacokinetic analysis of the anti-FGFR2b antibody bemarituzumab in patients from phase 1 to phase 2 trials.

Cancer chemotherapy and pharmacology

Xiang H, Liu L, Gao Y, Ahene A, Collins H.
PMID: 34383128
Cancer Chemother Pharmacol. 2021 Nov;88(5):899-910. doi: 10.1007/s00280-021-04333-y. Epub 2021 Aug 12.

PURPOSE: A population pharmacokinetic (PK) analysis of the anti-fibroblast growth factor receptor 2b antibody, bemarituzumab, was performed to evaluate the impact of covariates on the PK and assess whether dose adjustment is necessary for a future phase 3 trial.METHODS:...

Cite
Xiang H, Liu L, Gao Y, et al. Covariate effects and population pharmacokinetic analysis of the anti-FGFR2b antibody bemarituzumab in patients from phase 1 to phase 2 trials. Cancer Chemother Pharmacol. 2021;88(5):899-910doi: 10.1007/s00280-021-04333-y.
Xiang, H., Liu, L., Gao, Y., Ahene, A., & Collins, H. (2021). Covariate effects and population pharmacokinetic analysis of the anti-FGFR2b antibody bemarituzumab in patients from phase 1 to phase 2 trials. Cancer chemotherapy and pharmacology, 88(5), 899-910. https://doi.org/10.1007/s00280-021-04333-y
Xiang, Hong, et al. "Covariate effects and population pharmacokinetic analysis of the anti-FGFR2b antibody bemarituzumab in patients from phase 1 to phase 2 trials." Cancer chemotherapy and pharmacology vol. 88,5 (2021): 899-910. doi: https://doi.org/10.1007/s00280-021-04333-y
Xiang H, Liu L, Gao Y, Ahene A, Collins H. Covariate effects and population pharmacokinetic analysis of the anti-FGFR2b antibody bemarituzumab in patients from phase 1 to phase 2 trials. Cancer Chemother Pharmacol. 2021 Nov;88(5):899-910. doi: 10.1007/s00280-021-04333-y. Epub 2021 Aug 12. PMID: 34383128; PMCID: PMC8484135.
Copy Download .nbib Format: NLM
Population pharmacokinetic and exposure-response analyses of elotuzumab plus pomalidomide and dexamethasone for relapsed and refractory multiple myeloma.

Cancer chemotherapy and pharmacology

Ide T, Osawa M, Sanghavi K, Vezina HE.
PMID: 34825942
Cancer Chemother Pharmacol. 2021 Nov 26; doi: 10.1007/s00280-021-04365-4. Epub 2021 Nov 26.

PURPOSE: Elotuzumab plus pomalidomide/dexamethasone (E-Pd) demonstrated efficacy and safety in relapsed and refractory multiple myeloma (RRMM). The clinical pharmacology of elotuzumab [± lenalidomide/dexamethasone (Ld)] was characterized previously. These analyses describe elotuzumab population pharmacokinetics (PPK), the effect of Pd, and...

Cite
Ide T, Osawa M, Sanghavi K, et al. Population pharmacokinetic and exposure-response analyses of elotuzumab plus pomalidomide and dexamethasone for relapsed and refractory multiple myeloma. Cancer Chemother Pharmacol. 2021;doi: 10.1007/s00280-021-04365-4.
Ide, T., Osawa, M., Sanghavi, K., & Vezina, H. E. (2021). Population pharmacokinetic and exposure-response analyses of elotuzumab plus pomalidomide and dexamethasone for relapsed and refractory multiple myeloma. Cancer chemotherapy and pharmacology, . https://doi.org/10.1007/s00280-021-04365-4
Ide, Takafumi, et al. "Population pharmacokinetic and exposure-response analyses of elotuzumab plus pomalidomide and dexamethasone for relapsed and refractory multiple myeloma." Cancer chemotherapy and pharmacology vol. (2021). doi: https://doi.org/10.1007/s00280-021-04365-4
Ide T, Osawa M, Sanghavi K, Vezina HE. Population pharmacokinetic and exposure-response analyses of elotuzumab plus pomalidomide and dexamethasone for relapsed and refractory multiple myeloma. Cancer Chemother Pharmacol. 2021 Nov 26; doi: 10.1007/s00280-021-04365-4. Epub 2021 Nov 26. PMID: 34825942.
Copy Download .nbib Format: NLM
Correlation between immune-related adverse events and the efficacy of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: systematic review and meta-analysis.

Cancer chemotherapy and pharmacology

Zhang Q, Wang W, Yuan Q, Li L, Wang YC, Chi CZ, Xu CH.
PMID: 34821962
Cancer Chemother Pharmacol. 2022 Jan;89(1):1-9. doi: 10.1007/s00280-021-04375-2. Epub 2021 Nov 25.

OBJECTIVE: Anti-programmed cell death-1 and programmed cell death ligand-1 (PD-1/PD-L1) inhibitors have been proved to have a significant clinical efficacy in the treatment of non-small cell lung cancer (NSCLC). Many studies have demonstrated that immune-related adverse events (irAEs) are...

Cite
Zhang Q, Wang W, Yuan Q, et al. Correlation between immune-related adverse events and the efficacy of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: systematic review and meta-analysis. Cancer Chemother Pharmacol. 2021;89(1):1-9doi: 10.1007/s00280-021-04375-2.
Zhang, Q., Wang, W., Yuan, Q., Li, L., Wang, Y. C., Chi, C. Z., & Xu, C. H. (2022). Correlation between immune-related adverse events and the efficacy of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: systematic review and meta-analysis. Cancer chemotherapy and pharmacology, 89(1), 1-9. https://doi.org/10.1007/s00280-021-04375-2
Zhang, Qian, et al. "Correlation between immune-related adverse events and the efficacy of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: systematic review and meta-analysis." Cancer chemotherapy and pharmacology vol. 89,1 (2022): 1-9. doi: https://doi.org/10.1007/s00280-021-04375-2
Zhang Q, Wang W, Yuan Q, Li L, Wang YC, Chi CZ, Xu CH. Correlation between immune-related adverse events and the efficacy of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: systematic review and meta-analysis. Cancer Chemother Pharmacol. 2022 Jan;89(1):1-9. doi: 10.1007/s00280-021-04375-2. Epub 2021 Nov 25. PMID: 34821962.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 121 entries